(Total Views: 257)
Posted On: 02/12/2019 1:33:23 PM
Post# of 36566
It's great for investors to call in with questions, but there are many reasons people can not. I'd like the company to lay it all out there without waiting to be asked by phone in callers:
1. what is going on with NGIO - IPO price and date, rights offering? What percent is GNBT retaining?
2. explain more about Alpha Capital - how did they manipulate the price and harm us in other ways? What action is happening regarding them?
3. what is the latest on that "big fish" acquisition? Other acquisitions?
4. For the AE37/Keytruda phase 2 trial - what would be the most optimistic outcome? If there are early positive results is it possible the FDA would grant breakthrough therapy status and end it early?
5. Is any work being done to find a partner for Oralyn in order to finance another clinical trial? do a possible spinoff? Why don't other pharma companies seem interested in something that seems like a no-brainer?
6. When will we expect Excellogen revenues? Do we have a contract with the VA yet?
1. what is going on with NGIO - IPO price and date, rights offering? What percent is GNBT retaining?
2. explain more about Alpha Capital - how did they manipulate the price and harm us in other ways? What action is happening regarding them?
3. what is the latest on that "big fish" acquisition? Other acquisitions?
4. For the AE37/Keytruda phase 2 trial - what would be the most optimistic outcome? If there are early positive results is it possible the FDA would grant breakthrough therapy status and end it early?
5. Is any work being done to find a partner for Oralyn in order to finance another clinical trial? do a possible spinoff? Why don't other pharma companies seem interested in something that seems like a no-brainer?
6. When will we expect Excellogen revenues? Do we have a contract with the VA yet?
(0)
(0)
